Review: T-cell senescence, organ aging and proposed interventions
This review links T-cell senescence to organismal aging via chronic low-grade inflammation and reduced immune surveillance of senescent cells, and summarizes preclinical and early-stage human intervention studies. [1]
Automatic summary · not editorially reviewed
The key findings
T-cell senescence is strongly linked to organismal aging through chronic low-grade inflammation and reduced immune surveillance of senescent cells. [1]
Preclinical mouse studies showed that modulating T-cell immunosenescence can ameliorate age-related diseases, and early-stage human studies suggest possible health benefits. [1]
In mouse models of Alzheimer's disease, brain-infiltrating T cells may promote or protect depending on disease stage. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- T cells in organismal aging, mouse models and early-stage human studies
- Summary based on
- Study abstract
- Original publication
- April 24, 2026
T-cell senescence and organismal aging links
The review states that T-cell senescence is strongly linked to organismal aging through two interconnected processes: chronic low-grade inflammation and reduced immune surveillance of senescent cells. T cells are described as particularly vulnerable to thymic involution, aging of blood-forming stem cells, repeated homeostatic proliferation, chronic antigenic stimulation, and metabolic and mitochondrial dysfunction. As a result, aged T cells may lose their capacity to fight infection and to eliminate senescent cells, while also contributing to inflammaging through inflammatory cytokines.
Supporting source [1]
Preclinical and early human intervention findings
Recent preclinical studies in mouse models showed that modulating T-cell immunosenescence can ameliorate age-related diseases, according to the review. The approaches named are PD-1/PD-L1 blockade, senolytic chimeric antigen receptor T (CAR-T) cells, and CXCL4/platelet factor 4 (PF4). In addition, early-stage human clinical studies of caloric restriction, low-dose mTOR inhibition, thymic regeneration, and mesenchymal stromal/stem cell (MSC) therapy suggest that interventions targeting immunosenescence may provide health benefits. These are described as suggestions from early-stage studies, not established human benefits.
Supporting source [1]
Brain aging and review scope
In mouse models of Alzheimer's disease, T cells infiltrating the brain may have either disease-promoting or protective effects depending on the disease stage, the review notes, highlighting an intersection between T-cell-mediated immunosenescence and brain aging. The review summarizes basic concepts of immunosenescence, the molecular basis of immune surveillance of senescent cells, age-associated T-cell subsets, their links to brain aging, and interventional strategies aimed at clinical translation, with particular emphasis on T-cell biology and the transcriptional regulatory network driven by NR4a.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The intervention findings come from preclinical mouse models and early-stage human studies, so they do not establish human lifespan or disease benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ohyagi M, Ito M, Yoshimura A. · europepmc.org · April 24, 2026